Clovis Upgraded At Credit Suisse Following Acquisition Rumor

By: via Benzinga
Clovis Oncology Inc (NASDAQ: CLVS) is a potential takeout target for a global pharma company, Credit Suisse’s Kennen MacKay ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.